Morgan Stanley Genprex, Inc. Transaction History

Morgan Stanley

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Aug 16, 2024	BUY	$0.19 - $0.37 $11,297 - $21,999	59,459 New	59,459 $13,000
Q4 2023 Feb 13, 2024	BUY	$0.19 - $0.37 $2,777 - $5,408	14,618 Added 32.6%	59,459 $13,000
Q3 2023 Nov 15, 2023	BUY	$0.37 - $1.04 $7,412 - $20,834	20,033 Added 80.75%	44,841 $17,000
Q2 2023 Aug 14, 2023	BUY	$0.74 - $1.1 $8,288 - $12,320	11,200 Added 82.3%	24,808 $23,000
Q1 2023 May 15, 2023	BUY	$0.76 - $1.78 $530 - $1,242	698 Added 5.41%	13,608 $12,000
Q4 2022 Feb 14, 2023	BUY	$1.0 - $58.8 $1,590 - $93,492	1,590 Added 14.05%	12,910 $18,000
Q3 2022 Nov 14, 2022	SELL	$1.32 - $58.0 $8,053 - $353,858	-6,101 Reduced 35.02%	11,320 $16,000
Q2 2022 Oct 27, 2022	SELL	$1.28 - $2.31 $20,609 - $37,193	-16,101 Reduced 48.03%	17,421 $25,000
Q2 2022 Aug 15, 2022	SELL	$1.28 - $2.31 $20,609 - $37,193	-16,101 Reduced 48.03%	17,421 $25,000
Q1 2022 Oct 27, 2022	BUY	$1.82 - $3.5 $29,303 - $56,353	16,101 Added 92.42%	33,522 $76,000
Q1 2022 May 13, 2022	SELL	$1.82 - $3.5 $1.5 Million - $2.89 Million	-826,592 Reduced 96.1%	33,522 $76,000
Q4 2021 Feb 14, 2022	BUY	$1.21 - $2.7 $924,438 - $2.06 Million	763,999 Added 794.88%	860,114 $1.13 Million
Q3 2021 Nov 15, 2021	BUY	$2.59 - $3.36 $248,937 - $322,946	96,115 New	96,115 $257,000

600

Ticker GNPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,020,300
Market Cap $39.9M
Description
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incor...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.